Novo Nordisk gains full rights to Ziylos early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars
The acquisition supports Novo Nordisk's goal to develop glucose responsive insulins
Parts of the research activities in Ziylo have been spun out in a new company, Carbometrics that has entered into a research collaboration with Novo Nordisk to optimise glucose binding molecules.
Carbometrics has licenced rights for all non-therapeutic uses of glucose binding molecules including applications in diagnostics and glucose monitoring
"We believe the glucose binding molecules discovered by the Ziylo team together with Novo Nordisk world-class insulin capabilities have the potential to lead to the development of glucose responsive insulins which we hope can remove the risk of hypoglycaemia and ensure optimal glucose control for people with diabetes," said Marcus Schindler, senior vice president, Global Drug Discovery, Novo Nordisk.
"Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications, and it brings hope of a truly groundbreaking treatment to diabetes patients," said Harry Destecroix, PhD, chief executive officer and co-founder of Ziylo. "Novo Nordisk is the leader in the diabetes field, with deep clinical development and regulatory expertise and an established commercial infrastructure to deliver important new therapies to patients."
News details
